| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 560,000 | -- | 560,000 |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 10,000 | -- | -- |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 5,000 | -- | -- |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 10,210 | -- | -- |
| Apr 01, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
| Sep 03, 2020 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| Oct 01, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 23,230 | -- | 23,230 |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 5,941 | -- | 7,354 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.